JW Shinyak Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
JW Shinyak's earnings have been declining at an average annual rate of -47%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 0.4% per year. JW Shinyak's return on equity is 15.4%, and it has net margins of 2.9%.
Anahtar bilgiler
-47.0%
Kazanç büyüme oranı
-46.9%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 11.3% |
Gelir büyüme oranı | 0.4% |
Özkaynak getirisi | 15.4% |
Net Marj | 2.9% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Unpleasant Surprises Could Be In Store For JW Shinyak Corporation's (KOSDAQ:067290) Shares
Sep 16Is JW Shinyak (KOSDAQ:067290) A Risky Investment?
Mar 04Factors Income Investors Should Consider Before Adding JW Shinyak Corporation (KOSDAQ:067290) To Their Portfolio
Jan 28Don't Race Out To Buy JW Shinyak Corporation (KOSDAQ:067290) Just Because It's Going Ex-Dividend
Dec 24What Type Of Returns Would JW Shinyak's(KOSDAQ:067290) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Dec 07Gelir ve Gider Dağılımı
JW Shinyak nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 97,673 | 2,825 | 34,240 | 2,485 |
31 Mar 24 | 103,117 | -36,279 | 36,316 | 2,700 |
31 Dec 23 | 104,235 | -37,357 | 37,670 | 2,904 |
30 Sep 23 | 107,086 | -36,223 | 38,347 | 2,878 |
30 Jun 23 | 105,604 | -37,104 | 38,950 | 2,733 |
31 Mar 23 | 102,661 | 684 | 38,420 | 2,538 |
31 Dec 22 | 102,710 | 1,400 | 38,119 | 2,612 |
30 Sep 22 | 101,568 | 1,715 | 38,015 | 2,262 |
30 Jun 22 | 101,300 | 2,528 | 36,935 | 2,700 |
31 Mar 22 | 101,868 | 2,580 | 37,730 | 2,880 |
31 Dec 21 | 100,966 | 884 | 37,674 | 3,134 |
30 Sep 21 | 99,208 | -3,111 | 38,393 | 3,678 |
30 Jun 21 | 102,190 | -3,344 | 39,543 | 2,950 |
31 Mar 21 | 104,121 | -2,837 | 39,261 | 2,849 |
31 Dec 20 | 103,803 | -6,446 | 39,818 | 2,593 |
30 Sep 20 | 106,035 | -2,482 | 41,568 | 2,001 |
30 Jun 20 | 104,066 | -1,637 | 41,505 | 2,198 |
31 Mar 20 | 103,546 | -3,544 | 42,250 | 2,194 |
31 Dec 19 | 102,531 | 1,442 | 41,891 | 2,233 |
30 Sep 19 | 99,622 | -5,226 | 40,801 | 2,155 |
30 Jun 19 | 95,312 | -7,547 | 40,165 | 2,168 |
31 Mar 19 | 91,624 | -6,294 | 38,959 | 2,113 |
31 Dec 18 | 91,776 | -7,509 | 38,903 | 2,172 |
30 Sep 18 | 84,709 | -4,999 | 39,183 | 2,316 |
30 Jun 18 | 83,805 | -5,439 | 39,267 | 2,333 |
31 Mar 18 | 79,307 | -4,851 | 38,753 | 2,102 |
31 Dec 17 | 76,843 | -6,079 | 37,441 | 1,785 |
30 Sep 17 | 78,791 | -4,083 | 36,843 | 1,433 |
30 Jun 17 | 78,558 | -4,117 | 36,431 | 1,374 |
31 Mar 17 | 82,414 | -2,985 | 36,486 | 1,535 |
31 Dec 16 | 83,385 | -618 | 36,705 | 1,566 |
30 Sep 16 | 83,370 | -1,497 | 36,006 | 1,840 |
30 Jun 16 | 80,930 | -238 | 35,042 | 1,801 |
31 Mar 16 | 78,773 | 487 | 34,379 | 1,722 |
31 Dec 15 | 76,945 | 256 | 34,544 | 1,732 |
30 Sep 15 | 75,648 | 2,214 | 34,732 | 1,527 |
30 Jun 15 | 75,489 | 3,232 | 33,581 | 1,738 |
31 Mar 15 | 74,776 | 542 | 33,640 | 1,913 |
31 Dec 14 | 73,018 | -527 | 32,627 | 2,250 |
30 Sep 14 | 74,742 | 1,037 | 31,354 | 2,399 |
30 Jun 14 | 73,309 | -2,572 | 32,043 | 2,310 |
31 Mar 14 | 71,882 | -2,577 | 30,836 | 1,791 |
31 Dec 13 | 70,695 | -3,068 | 30,299 | 1,910 |
Kaliteli Kazançlar: A067290 has high quality earnings.
Büyüyen Kar Marjı: A067290 became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: A067290 has become profitable over the past 5 years, growing earnings by -47% per year.
Büyüme Hızlandırma: A067290 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: A067290 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).
Özkaynak Getirisi
Yüksek ROE: A067290's Return on Equity (15.4%) is considered low.